.jpg "uniQure NV (NASDAQ: QURE)")
Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating on uniQure NV (QURE) today and set a price target of $81. The company’s shares opened today at $57.55, close to its 52-week high of $60.95.
Piros observed:
“: We reiterate our OW rating and $81 PT on uniQure. This morning, Spark (Neutral) filed a 14D-9, which detailed a timeline (Figure 1) of potential partnership and acquisition talks the company had. Our key takeaway is that four parties, including Roche (RHHBY – NC) were in discussions regarding a co- development and co-promotion partnership relating to hemophilia A. Three of these parties (including Roche) were involved in acquisition talks. This detailed process indicates there is an immense interest in hemophilia gene therapy programs from pharma.”
According to TipRanks.com, Piros is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -4.3% and a 41.2% success rate. Piros covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Proteostasis Therapeutics Inc, and Strongbridge Biopharma Plc.
Currently, the analyst consensus on uniQure NV is a Strong Buy with an average price target of $74, a 28.6% upside from current levels. In a report issued on February 25, H.C. Wainwright also maintained a Buy rating on the stock with a $73 price target.
See today’s analyst top recommended stocks >>
Based on uniQure NV’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $21.89 million. In comparison, last year the company had a GAAP net loss of $27.47 million.
Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded on January 9, 2012 and is headquartered in Amsterdam, the Netherlands.
